Synbio International Inc. (OTC: SYIN) announced the appointment of Dr. Nick Vatakis, MD as Medical Director and board member. The psychiatrist brings nearly three decades of clinical and research experience, having served as principal investigator on more than 200 clinical trials across psychiatric and neurological conditions.
Dr. Vatakis is recognized for his expertise in psychopharmacology and multimodal psychotherapy. He previously founded and served as Chief Medical Officer of a clinical research organization in Eastern Europe and has advised numerous drug development programs.
“Nick’s vast experience in clinical research and psychiatry enhances our credibility with regulators, partners, and investors alike,” the company said.
Dr. Vatakis will oversee the design and execution of Synbio’s upcoming feasibility trial for its AI-driven facial analysis depression screening software, ensuring adherence to ethical, medical, and scientific standards.
Synbio International focuses on clinically validated, AI-driven medical diagnostics pursued through strategic partnerships and research collaborations.
This release may contain forward-looking statements within the meaning of applicable securities laws, including statements regarding Synbio International Inc.’s business strategy, product development, clinical trial plans, and future operations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and readers should not place undue reliance on them. Synbio undertakes no obligation to update any forward-looking statement except as required by law.
For informational purposes only — this release is republished from the company’s official disclosures and public news distribution. Investors should refer to Synbio International’s filings on the Investors page and on OTC Markets for complete and current information.